Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02561286 · ClinicalTrials.gov registry record · NA

Being Responsible for Ourselves HIV Risk Reduction for Black MSM

A NA study, sponsored by University of Pennsylvania.

Completed
Registry status
NA
Development phase
595
Enrollment target

NCT02561286: Completed NA study, sponsored by University of Pennsylvania.

NCT02561286 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 595 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02561286, a NA study, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
NA
Development phase
595 participants
Enrollment target

Study Summary

The incidence of HIV/AIDS among African American men who have sex with men (MSM) is alarming, and the public health response to this urgent situation has been hampered by a lack of sexual risk reduction interventions with solid evidence of efficacy in this population. Accordingly, the broad, long-term objective of the proposed research is to identify interventions to reduce the risk of sexually transmitted infection (STI) among African American MSM. This application seeks funds to develop and test the efficacy of a theory-based, contextually appropriate behavioral intervention to reduce sexual risk behavior among African American MSM. Intervention development will be guided by social cognitive theory, the theory of planned behavior, qualitative information from focus groups, and findings from a longitudinal survey of men from the study population. A one-on-one intervention will be utilized to address the specific prevention needs of each man and to allay participants' concerns about revealing their sexual involvement with men by virtue of participating in a group or workshop intervention. The study will utilize a randomized controlled trial design, with baseline, immediate post intervention, and 6 and 12 months post intervention assessments. The participants will be African American MSM who will be randomized to a one-on-one sexual risk reduction intervention or a one-on-one health promotion intervention that will serve as the control condition. The primary outcome is consistent condom use during anal and vaginal intercourse. The study will test whether the intervention increases the consistent use of condoms during anal intercourse, the primary outcome, whether it decreases other sexual risk behaviors, and whether social cognitive theory variables mediate the effects of the intervention on consistent condom use. This study will provide an urgently needed intervention to reduce the risk of HIV and other STIs in one of the highest risk populations in the United State

Primary Outcome

Men who reported at least one intercourse act and whose number of reported protected acts equaled their number of acts were coded as practicing consistent condom use. Men who reported at least one intercourse act and whose reported number of protected acts was less than their number of acts were coded as not practicing consistent condom use.

Interventions

  • BEHAVIORAL Health Promotion Intervention
  • BEHAVIORAL BRO HIV Risk Reduction Intervention

Trial Details

FieldValue
Enrollment Target 595 participants
Start Date 2008-04
Est. Completion 2012-05
Phase NA
University of Pennsylvania

1,423 total trials

What the finished NCT02561286 record still lists

NCT02561286 is an interventional study that assigns participants to a tested intervention. The registered 595 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (58% lower).

The record links to 0 conditions, and to 2 interventions - of which Health Promotion Intervention is the first listed.

NCT02561286 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02561286 about?

NCT02561286 is a clinical study titled "Being Responsible for Ourselves HIV Risk Reduction for Black MSM". The incidence of HIV/AIDS among African American men who have sex with men (MSM) is alarming, and the public health response to this urgent situation has been hampered by a lack of sexual risk reduction interventions with solid evidence of efficacy in this population. Accordingly, the broad, long-te...

What is the current status of trial NCT02561286?

This trial is currently completed. It is a NA study. The enrollment target is 595 participants. The study started on 2008-04. Estimated completion is 2012-05.

What interventions are being tested in trial NCT02561286?

The interventions under investigation include: Health Promotion Intervention (BEHAVIORAL), BRO HIV Risk Reduction Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT02561286?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02561286's enrollment target sits among peer trials

595 174th of 2000 higher than 1,827 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05723198 · 595 participants · Phase 3

    A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

  • NCT02138734 · 596 participants · Phase 1

    A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

  • NCT06797245 · 596 participants · NA

    APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women

  • NCT07100080 · 596 participants · Phase 2

    Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02561286, the US trial registry maintained by the National Library of Medicine. NCT02561286 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.